Articles related to Behavioral Health

Research examining cannabis and sexual function suggests possible associations with increased sexual frequency and orgasm satisfaction in some users, but findings remain inconsistent, largely observational, and influenced by dose, timing, formulation, and individual factors.

Experts reviewing available evidence suggest melatonin and magnesium may support sleep through different mechanisms, though benefits appear dependent on the underlying cause of sleep disturbance and overall evidence remains mixed, particularly for magnesium.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Prior ayahuasca experience was associated with lower self-reported depression, stress, and alcohol use among Brazilian ceremony participants, while also correlating with stronger spiritual wellbeing and metaphysical beliefs in an observational study that did not establish causality.

A report examining a celebrity-backed sports prediction campaign highlights concerns about increasing youth exposure to gambling-related marketing. The article connects growing gambling participation among adolescents and young adults with evidence linking gambling disorder to adverse mental health outcomes, including suicidality.